Please login to the form below

Not currently logged in


This page shows the latest Fampyra news and features for those working in and with pharma, biotech and healthcare.

NICE denies two drugs in new MS guidance

NICE denies two drugs in new MS guidance

Sativex and Fampyra too costly for NHS in England. Two drugs were deemed too expensive for NHS use in new guidance intended to tackle the inequality of multiple sclerosis (MS) care ... Michelle Mitchell, chief executive of the MS Society, said: “NICE's

Latest news

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...